334936-05-9

Upstream product

• 334935-96-5 6-(tert-butyl-diphenyl-silanyloxy)-3-methyl-hexanal 
• 1730-25-2 allylmagnesium bromide 
• 334935-94-3 6-(tert-butyl-diphenyl-silanyloxy)-3-methyl-hexanoic acid methyl ester 
• 56994-89-9 (S)-(-)-citronellic acid,methyl ester 
• 5949-05-3 (S)-Citronellal 
• 24850-33-7 allyltributylstanane 
• 158661-84-8 methyl (S)-6-hydroxy-3-methylhexanoate 

Downstream Products

• 334936-07-1 tert-Butyl-[(4S,6S)-6-(1-methoxy-allyloxy)-4-methyl-non-8-enyloxy]-diphenyl-silane 
• 334936-16-2 (Z)-4-{(2R,6R)-6-[(S)-5-(tert-Butyl-diphenyl-silanyloxy)-2-methyl-pentyl]-5,6-dihydro-2H-pyran-2-yl}-but-2-enoic acid 2,4-dimethoxy-benzyl ester 
• 334936-12-8 (Z)-4-{(2R,6R)-6-[(S)-5-(tert-Butyl-diphenyl-silanyloxy)-2-methyl-pentyl]-5,6-dihydro-2H-pyran-2-yl}-but-2-enoic acid methyl ester 
• 334936-22-0 (Z)-4-[(2R,6R)-6-((S)-4-Hydroxymethyl-2-methyl-pent-4-enyl)-5,6-dihydro-2H-pyran-2-yl]-but-2-enoic acid 2,4-dimethoxy-benzyl ester 
• 334936-20-8 (Z)-4-[(2R,6R)-6-((S)-4-Formyl-2-methyl-pent-4-enyl)-5,6-dihydro-2H-pyran-2-yl]-but-2-enoic acid 2,4-dimethoxy-benzyl ester 
• 334936-31-1 (Z)-4-[(2R,6R)-6-((S)-5-Hydroxy-2-methyl-pentyl)-5,6-dihydro-2H-pyran-2-yl]-but-2-enoic acid 2,4-dimethoxy-benzyl ester 
• 334936-03-7 {6-[5-(tert-butyl-diphenyl-silanyloxy)-2-methyl-pentyl]-5,6-dihydro-2H-pyran-2-yl}-acetaldehyde 
• 334936-18-4 (Z)-4-[(2R,6R)-6-((S)-2-Methyl-5-oxo-pentyl)-5,6-dihydro-2H-pyran-2-yl]-but-2-enoic acid 2,4-dimethoxy-benzyl ester 
• 334936-09-3 tert-butyl-[5-(6-methoxy-3,6-dihydro-2H-pyran-2-yl)-4-methyl-pentyloxy]-diphenyl-silane 

Relevant academic research and scientific papers

LAULIMALIDE ANALOGS AND USES THEREOF

The present invention provides compounds having formula 1: (I) and pharmaceutically acceptable derivatives thereof, wherein R1-R10, q, t, X0, X1, A, B, D, E, G, J, K, L, M and Z are as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of disorders associated with cellular hyperproliferation.

Synthetic studies toward the microtubule-stabilizing agent laulimalide: Synthesis of the C1-C14 fragment

The C1-C14 fragment of the paclitaxel-like antimicrotubule agent laulimalide has been synthesized in 15 steps from L-(-)-citronellal. The C9 chiral center was established using an asymmetric allylation, the dihydropyran ring was prepared through ring-closing metathesis, and the exo-methylene was incorporated using Eschenmoser's salt.